Looking for funding opportunities for your innovative research? NIH’s High-Risk, High-Reward Program Is Finally Back!

By Bouvier Grant Group

We stay current on NIH happenings and would be delighted to keep you informed.

Good news for the boldest ideas in your research portfolio: the NIH Common Fund’s High-Risk, High-Reward Research (HRHR) program has reissued its full slate of funding opportunities for FY2026. If you’ve got ideas that are more “paradigm shift” than “safe bet,” this program is built for you.

The program spans four distinct awards, each with its own deadline this cycle:

  • NIH Director’s Pioneer Award (DP1) — for investigators at any career stage proposing bold new research directions. Due September 9, 2026.
  • NIH Director’s New Innovator Award (DP2) — for early-career, early stage investigators with high-impact, innovative project ideas. Due August 17, 2026.
  • NIH Director’s Transformative Research Award (TR01) — for individuals or teams pursuing unconventional, paradigm-challenging research. Due September 3, 2026.
  • NIH Director’s Early Independence Award (DP5) — for exceptional junior scientists ready to skip the postdoc and launch an independent lab. Due September 10, 2026.

These mechanisms are very competitive but worth pursuing if they are a good fit. Last year, I had a client with a truly innovative idea who kept getting triaged on the parent R01. I suggested the TR01 and he landed it! It may seem counterintuitive to suggest a more competitive mechanism for a project that keeps getting triaged at the parent R01. But fit to the mechanism is of paramount importance!

Remember that while you cannot have the same science in review at the same time at two different places in NIH, you can submit simultaneously to NIH and another federal agency or a private foundation. Some federal agencies welcome risk (e.g., CDMRP), as do some foundations. It might be worth considering a shotgun approach when seeking funding for a high-risk idea.

Note the deadlines above for the HRHR portfolio, which are coming up quickly! They each have a SINGLE deadline per year, so get cracking! We’ll be featuring each of these opportunities in upcoming content, breaking down what reviewers are really looking for and how to position your application within a tight window. So keep checking back — and if one of these deadlines has your name on it, now’s the time to start drafting.

Dr. Meg Bouvier

Author:
Dr. Meg Bouvier

Margaret Bouvier received her PhD in 1995 in Biomedical Sciences from the Mount Sinai School of Medicine. After an NINDS post-doctoral fellowship, she worked as a staff writer for long-standing NIH Director Dr. Francis Collins in the Office of Press, Policy, and Communications for the Human Genome Project and NHGRI. Since 2007, Meg has specialized in editing and advising on NIH submissions, and began offering virtual courses in 2015.

She’s recently worked with more than 25% of the nation’s highest-performing hospitals*, three of the top 10 cancer hospitals*, three of the top 16 medical schools for research*, and 8 NCI-Designated Cancer Centers.

Her experience at NIH as both a bench scientist and staff writer greatly informs her approach to NIH grantwriting. She has helped clients land over half a billion in federal funding. Bouvier Grant Group is a woman-owned small business.

*As recognized by the 2024/25 US News & World Report honor roll.

Categories:
Bouvier Grant Group logo white
Scroll to Top
We read all NIH notices for our clients. When you join our mailing list, we’ll pass along important changes directly to your inbox, as well as opportunities to improve your grantsmanship skills.
Primary Position
Lead Source

Wait!

Subscribe to our monthly newsletter for the latest NIH news, grantwriting tips, and more.

Newsletter Popup